Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 8  |  Issue : 2  |  Page : 112-118

Clinical evaluation of autologous platelet-rich fibrin and perioglas® in treating periodontal intrabony defects


Department of Periodontology and Oral Implantology, The Oxford Dental College, Bengaluru, Karnataka, India

Correspondence Address:
Dr. Shravanthi Raghav Yajamanya
Department of Periodontology and Oral Implantology, The Oxford Dental College, Bengaluru, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/njecp.njecp_31_20

Rights and Permissions

Context: This study was conducted to compare autologous platelet-rich fibrin (PRF) with PerioGlas® in treating periodontal intrabony defects (IBDs) of variable number of walls, based on clinical and radiographic outcomes. Aim: The aim of the study was to assess which regenerative material, i.e., autologous PRF or PerioGlas®, has a broader range of applicability in treating periodontal IBDs. Settings and Design: This study is a randomized controlled trial conducted at the Department of Periodontology and Oral Implantology of the Oxford Dental College and Hospital, Bangalore, India. Methods: Sixty IBDs were provided nonsurgical periodontal treatment, i.e., scaling and root planing, followed by oral hygiene instructions. When performing periodontal surgery, the IBDs were assigned to the Control group (i.e., access flap alone), test Group I (i.e., access flap + (PerioGlas®), and test Group II (i.e., access flap + autologous PRF). The vertical bone defects in three groups consisted of 3-, 2-, and 1-wall intrabony periodontal defects. Radiographic assessments were performed at baseline and 6 and 9 months. Statistical Analysis Used: Statistical analysis was based on the mean values, standard deviation, and P values. Results: Mean defect depth fill compared to baseline and 9 months postoperatively for: (1) 3-wall IBDs: Control group was 6.50 ± 1.56 mm, test Group I was 9.27 ± 1.62 mm, and test Group II was 10.45 ± 2.33 mm, (2) 2-wall IBDs: Control group was 6.08 ± 0.62 mm, test Group I was 8.21 ± 1.58 mm, and test Group II was 8.96 ± 1.85 mm, and (3) 1-wall IBDs: Control group was 5.78 ± 1.07 mm and test Group II was 8.00 ± 0.69 mm. Conclusion: Autologous PRF has a wider applicability in case of various types of IBDs as compared to PerioGlas® owing to its mechanism of action and composition which is the presence of various growth factors and cytokines.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed134    
    Printed2    
    Emailed0    
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal